Description
Clindovit Pharmacodynamics
Clindamycin is an antibiotic of the lincosamide group, active against all strains of Propionibacterium acnes, the minimum suppressive concentration (MSC) is 0.4 µg/ml.
Inhibits protein synthesis in the microbial cell due to interaction with 50S-subunits of ribosomes.
Clindamycin phosphate is inactive in vitro, but after application to the skin it is quickly hydrolyzed by phosphatases in the sebaceous gland ducts to form clindamycin, which has antibacterial activity. After application on the skin the amount of free fatty acids on the skin surface is reduced from about 14 to 2%.
Indications
The drug is used for the treatment of acne (acne vulgaris).
Contraindications
Hypersensitivity to clindamycin or lincomycin in anamnesis; Crohn’s disease, ulcerative and pseudomembranous colitis (including in anamnesis).
Caution
Under 12 years of age (no experience of use), lactation.
Caution should be exercised in patients with allergies and when concomitant administration of muscle relaxants.
Administration during pregnancy and lactation
Topical application of the gel during pregnancy is possible if the expected benefits to the mother outweigh the potential risks to the fetus. If it is necessary to use during lactation, it is recommended to stop breast-feeding.
Dosage and administration
- Outwardly. A thin layer of gel is applied to the affected area of pre-cleaned and dried skin 2-3 times a day.
- Course of treatment: to obtain satisfactory results, treatment should be continued for 6-8 weeks, and if necessary, can be continued for up to 6 months.
